文献速递艾滋病与性传播感染

肥胖对HIV感染者抗逆转录病毒药物药代动力学及免疫病毒学应答的影响:病例对照研究

Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

该病例对照研究纳入291例肥胖(BMI≥30 kg/m²)和196例正常体重(BMI 19-25 kg/m²)的HIV-1感染者,比较抗逆转录病毒药物血浆浓度及免疫病毒学应答。结果显示替诺福韦、依非韦伦和洛匹那韦的C12在肥胖组显著低于正常体重组,且C12/24低于疗效阈值的比例更高,但病毒学失败率无差异。

要点

  • 肥胖者替诺福韦、依非韦伦和洛匹那韦C12显著低于正常体重者。
  • 肥胖者抗逆转录病毒药物C12/24更常低于疗效阈值。
  • 尽管暴露较低,肥胖与正常体重者病毒学失败率无差异。

核心结论

  • 肥胖影响抗逆转录病毒药物血浆暴露,但未发现该亚optimal暴露对免疫病毒学控制有后果。

研究设计与样本

  • 病例对照研究,纳入2009-2012年医院数据库HIV-1感染者,肥胖组291例(BMI≥30 kg/m²),正常体重组196例(BMI 19-25 kg/m²)。

主要发现

  • 替诺福韦C12肥胖组66 ng/mL vs 正常体重组86 ng/mL(P<0.001)。
  • 依非韦伦C12肥胖组1498 ng/mL vs 正常体重组2034 ng/mL(P<0.001)。
  • 洛匹那韦C12肥胖组4595 ng/mL vs 正常体重组6420 ng/mL(P<0.001)。
  • 调整协变量后,肥胖组抗逆转录病毒药物C12/24低于疗效阈值的频率更高(P<0.001)。
  • 肥胖组CD4计数高于正常体重组(510 vs 444 cells/mm³,P<0.001),病毒学失败率无差异。

关键数值与推荐

  • 肥胖定义为BMI≥30 kg/m²,正常体重定义为BMI 19-25 kg/m²。

临床怎么用

  • 对肥胖HIV感染者应关注替诺福韦、依非韦伦和洛匹那韦的血浆暴露,但本研究未显示病毒学失败率增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity has high prevalence among HIV-infected patients. Increased adipose tissue mass affects the pharmacokinetics of numerous drugs, but few data are available for antiretroviral drugs. OBJECTIVES: In this study we aimed to explore the pharmacokinetics of antiretroviral drugs and the immuno-virological response in obese patients with HIV infection. PATIENTS AND METHODS: We examined data from 2009 to 2012 in our hospital's database for HIV-1-infected patients who received an antiretroviral drug (abacavir, emtricitabine, lamivudine, tenofovir, efavirenz, etravirine, nevirapine, atazanavir/ritonavir, darunavir/ritonavir, lopinavir/ritonavir or raltegravir). Obese patients were defined as those with BMI ≥30 kg/m 2 and normal-weight patients as those with BMI 19-25 kg/m 2 . Plasma concentrations ( C 12/24 ) were compared for each antiretroviral drug using a Mann-Whitney test. Suboptimal dosing and virological outcome were assessed by logistic regression, adjusting on covariates. RESULTS: We enrolled 291 obese and 196 normal-weight patients. Among the 12 analysed antiretroviral drugs, tenofovir, efavirenz and lopinavir C 12 values were significantly lower in obese than normal-weight patients: 66 versus 86 ng/mL, 1498 versus 2034 ng/mL and 4595 versus 6420 ng/mL, respectively ( P < 0.001). Antiretroviral drug C 12/24 values were more frequently below efficacy thresholds for obese than for normal-weight patients after adjustment for other covariates ( P < 0.001). Although obese patients showed a higher CD4 count than normal-weight patients (510 versus 444 cells/mm 3 , P < 0.001), the groups did not differ in virological failure rate. CONCLUSIONS: This study highlights the impact of obesity on antiretroviral drug plasma exposure, but identifies no consequence of this suboptimal exposure on the immuno-virological control in this population.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Madelain V, Le MP, Champenois K, et al. Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study. J Antimicrob Chemother. 2017. PMID: 28065890. doi:10.1093/jac/dkw527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。